Glucagon ELISA

Product Search

The Glucagon ELISA kit measures Glucagon (1-29) with no detectable cross-reactivity to Glicentin, Oxyntomodulin, GLP-1, GLP-2, or GRPP. Simple procedure, 2.5 hour incubations, no extraction needed, no special collection tube required. Relevant dynamic range and sensitivity.



Catalog Numbers

AL-157(RUO)-Instructions for Use
AL-157-i(CE)-Instructions for Use
AL-157-r(RUO)-Instructions for Use


96 well microtiter


HRP-based ELISA, colorimetric detection by dual wavelength absorbance at 450 nm and 630 nm as reference filter

Dynamic Range

6, 7-314 pg/mL

Species Reactivity

Enquire about animal-specific cross-reactivity

Limit of Detection

2.4 pg/mL

Sample Size

50 µL

Sample Type


Assay Time

2.5 hours

Shelf Life

24 months



Glucagon and Oxyntomodulin, a peptide hormone secreted by the alpha cells of pancreas, share identical amino acid sequence in the N-terminal 29 aa. Glucagon is a 29-amino acid polypeptide processed from proglucagon in pancreatic alpha cells.1 In intestinal L-cells proglucagon is cleaved into glicentin, corresponding to proglucagon residues no 1-69. Glicentin can further be processed into oxyntomodulin, corresponding to proglucagon residues no 33-69. These peptides are released simultaneously upon stimulation.

Glucagon has shown to have an effect opposite to that of insulin, i.e. it raises blood glucose levels. It causes the liver to convert glycogen into glucose, which is then released into the blood stream.2-4 During hypoglycaemia, glucagon secretion offers a protective feedback mechanism, defending the organism against damaging effects of glucose deficiency in the brain and nerves.5


  1. Sandoval DA and D’Alessio DA. Physiology of Proglucagon Peptides: Role of Glucagon and GLP-1 in Health and Disease. Physiol Rev 95:513-548.
  2. Bagger JI et al (2011) Glucagon antagonism as a potential therapeutic target in type 2 diabetes. Diabetes, Obesity and Metabolism 13:965-971.
  3. Holst J et al (2004) Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287: E199-206.
  4. Holst J (2010) Glucagon and Glucagon-Like Peptides 1 and 2. Results Probl Cell Differ 50:121-135.
  5. Young A (2005) Inhibition of Glucagon Secretion. Advances in Pharmacology 52:151-171.

Glucagon ELISA AL-157

Shah A, Dodson WC, Kris-Etherton PM, Kunselman AR, Stetter CM, Gnatuk CL, Estes SJ, Allison KC, Sarwer DB, Sluss PM, Coutifaris C, Dokras A, Legro RS. Effects of Oral Contraception and Lifestyle Modification on Incretins and TGF-ß Superfamily Hormones in PCOS. J Clin Endocrinol Metab. 2021 Jan 1;106(1):108-119. doi:
10.1210/clinem/dgaa682. PMID: 32968804; PMCID: PMC7765645

All Products Cited: Activin A ELISA AL-110; Activin AB ELISA AL-153; Inhibin A ELISA AL-123; Inhibin B ELISA AL-107; AMH ELISA AL-105, IGF-I ELISA AL-121, IGFBP-2 ELISA AL-140; GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Follistatin ELISA AL-117; Oxyntomodulin ELISA AL-139; Glucagon ELISA AL-157


D’Alessio D, Kumar A, Kalra B, Mistry S, Tong J. Novel ELISA Assays Demonstrate Specificity of Islet and Intestinal Processing of Proglucagon. Volume 4, Issue Supplement_1, April_May 2020, SUN-LB124,

All Products Cited: GLP-1 ELISA AL-172; Glucagon ELISA AL-157; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185


Upadhyay J, Panagiotou G, Anastasilakis A, Mantzoros C. Oxyntomodulin and Glucagon in Healthy Humans: Anthropometric, Hormonal, and Metabolic Predictors and Response to Glucose Load and Exercise. Abstract – ADA Supported Research, Integrated Physiology / Obesity. Not Dated

All Products Cited: Oxyntomodulin ELISA AL-139; Glucagon ELISA AL-157


Kumar A, Kalra B, Mistry S, Patel AS, Budhavarapu V, Chatterji T, Savjani G, Krishna R, D’Alessio D. Development of Novel Specific and Sensitive ELISAs for Proglucagon-Derived Peptides. Poster presented at 69th AACC Meeting; 2017 July 30-Aug 3; San Diego, CA

All Products Cited: Glucagon ELISA AL-157; GLP-1 ELISA AL-172; Oxyntomodulin ELISA AL-139


Upadhyay J, Perakakis N, Panagiotou G, Anastasilakis AD, Mantzoros CS. Regulation of the proglucagon-derived hormones in healthy and in obese after bariatric surgery. Poster Presentation. Unknown Conference

All Products Cited: Oxyntomodulin ELISA AL-139; Glucagon ELISA AL-157


Polyzos SA, Perakakis N, Boutari C, Kountouras J, Ghaly W, Anastasilakis AD, Karagiannis A, Mantzoros CS. Targeted Analysis of Three Hormonal Systems Identifies Molecules Associated with the Presence and Severity of NAFLD. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e390–400. doi: 10.1210/clinem/dgz172. PMID: 31690932;
PMCID: PMC7112980.

All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-157; MPGF ELISA AL-175; Oxyntomodulin ELISA AL-139; Follistatin-Like 3 ELISA AL-152; Activin B ELISA AL-150; IGF-I ELISA AL-121; Total IGFBP-3 ELISA AL-120; Intact IGFBP-3 ELISA AL-149; Total IGFBP-4 ELISA AL-126; Intact IGFBP-4 ELISA AL-128; picoPAPP-A ELISA AL-101


Kim S, Abbasi F, Nachmanoff C, Kumar A, Kalra B, Savjani G, Mantzoros C. Effect of Liraglutide Treatment on Proglucagon-Derived Peptides. JESOCI, Volume 4, Abstract Supplement, 2020

All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Glucagon ELISA AL-127; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; MPGF ELISA AL-175


Perakakis N, Kalra B, Angelidi AM, Kumar A, Gavrieli A, MYannakoulia M, Mantzoros CS. Methods paper: Performance characteristics of novel assays for circulating levels of proglucagon-derived peptides and validation in a placebo controlled cross-over randomized clinical trial. Metabolism, Volume 129, 2022, 155157, ISSN 0026-0495,

All Products Cited: GLP-1 ELISA AL-172; GLP-2 ELISA AL-174; Oxyntomodulin ELISA AL-139; Glicentin ELISA AL-185; Glucagon ELISA AL-127; MPGF ELISA AL-175; C-Peptide of Insulin ELISA AL-151

Technical Literature